Literature DB >> 761229

Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-beta-D-arabinofuranosylcytosine.

A W Harris, E C Reynolds, L R Finch.   

Abstract

Assays of thirteen cell lines, derived from mouse lymphomas, myelomas, myeloid tumors, and a mastocytoma, for sensitivity to growth inhibition by 1-beta-D-arabinofuranosylcytosine (ara-C) revealed a spectrum between the most and least sensitive which differed 100-fold from each other. An inverse correlation between sensitivity and cellular deoxycytidine 5'-triphosphate (dCTP) content was found, and this suggested that sensitivity of cells might be increased if the dCTP content was lowered during cell exposure to ara-C. Previous work has shown that thymidine treatment of cells lowers their dCTP content, and the effect of thymidine on the sensitivity of six of the cell lines to ara-C was therefore measured. Concentrations of thymidine below those inhibitory to cell growth by themselves caused an increase in ara-C sensitivity by up to 3-fold in 4 cell lines in which thymidine causes a depression in dCTP content but not in 2 myeloid lines in which the dCTP content was found not to be depressed by the same thymidine treatment. The results confirm an important role for dCTP in determining cellular sensitivity to ara-C. The finding that the sensitivity of 2 lymphoma cell lines to ara-C could be increased by concentrations of thymidine in the region of 10 micrometer, which are attainable clinically in humans, suggests that a combination of ara-C with thymidine might be useful in the treatment of some human tumors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761229

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Granulocyte-macrophage colony-stimulating factor elevates invariant chain expression in immature myelomonocytic cell lines.

Authors:  I Klagge; U Kopp; N Koch
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

Review 2.  A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Authors:  R J Fram
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

3.  Growth factor gene activation and clonal heterogeneity in an autostimulatory myeloid leukemia.

Authors:  K B Leslie; J W Schrader
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

4.  Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.

Authors:  J A Streifel; S B Howell
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

5.  Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate.

Authors:  S B Howell; S J Mansfield; R Taetle
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  A phase I-II study of combination therapy with thymidine and cytosine arabinoside.

Authors:  R Fram; P Major; E Egan; P Beardsley; D Rosenthal; D Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.

Authors:  J S Wiley; J Taupin; G P Jamieson; M Snook; W H Sawyer; L R Finch
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 8.  Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.

Authors:  P H Ellims
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Analysis of the drug synergism between thymidine and arabinosyl cytosine using mouse S49 T lymphoma mutants.

Authors:  A Cohen; B Ullman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines.

Authors:  D J Kemp; A W Harris; S Cory; J M Adams
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.